The Impact of PCSK9 Inhibition in Dyslipidemia Management
This Continuing Education activity is supported by an educational grant from Amgen.
This activity is supported by an educational grant from Amgen.
Joel C. Marrs, PharmD, FASHP, FCCP, FNLA, BCPS-AQ Cardiology, BCACP, CLS, ASH-CHC Associate ProfessorUniversity of Colorado Skaggs School of Pharmacy and Pharmaceutical SciencesAurora, Colorado
Medical Writing and Editorial Support
Jill Allen, PharmD Drug Information ConsultantPin Oak AssociatesSalt Lake City, Utah
After completing this continuing education program, the participant will be able to:
- Identify the appropriate patient population that will benefit from PCSK9 inhibitors, based on clinical trial data
- Differentiate the available PCSK9 inhibitors, focusing on their current indications, mechanisms of action, efficacy, safety, and administration
- Apply strategies to optimize patient outcomes with PCSK9 inhibitors
Target audience: Pharmacists, specialty pharmacists
Type of activity: Application
Release date: April 22, 2017
Expiration date: April 22, 2018
Estimated time to complete activity: 2.0 hours
Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-17-031-H01-P. The activity is available for CE credit through April 22, 2018.